Targeting SARS-CoV-2 differentlyGerman structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus’ main protease. more ➔
miRNAs unmask vulnerability in breast cancer stem cellsResearchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells more ➔
Janssen to pledge COVID-19 vaccine to African UnionJohnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). more ➔
Bispecific IgG switch off SARS-CoV-2 escape variantsA bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals. more ➔
Step Pharma SAS raises €35m in Series BKurma Partners-founded Step Pharma has baged €35m in a Series B financing to advance its blood cancer lead STP938. more ➔
Europe needs a strategyThe threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination … more ➔
AZD1222 claims 79% effecacy in pivotal US study Following assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US. more ➔
EMA recommends to continue AZD1222 vaccinationsOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine. more ➔
Novel COVID antibody enters clinical testingGerman CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days. more ➔
Don’t bet only on vaccines!First emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient … more ➔
